Etidronic acid
Etidronic acid structure
|
Common Name | Etidronic acid | ||
|---|---|---|---|---|
| CAS Number | 2809-21-4 | Molecular Weight | 206.028 | |
| Density | 2.1±0.1 g/cm3 | Boiling Point | 578.8±60.0 °C at 760 mmHg | |
| Molecular Formula | C2H8O7P2 | Melting Point | 198~199℃ | |
| MSDS | Chinese USA | Flash Point | 303.8±32.9 °C | |
| Symbol |
GHS05 |
Signal Word | Danger | |
|
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
J. Sci. Ind. Res. 65(10) , 808, (2006) Drug-induced liver injury (DILI) is a significant concern in drug development due to the poor concordance between preclinical and clinical findings of liver toxicity. We hypothesized that the DILI types (hepatotoxic side effects) seen in the clinic can be tra... |
|
|
Effects of various squalene epoxides on coenzyme Q and cholesterol synthesis.
Biochim. Biophys. Acta 1841(7) , 977-86, (2014) 2,3-Oxidosqualene is an intermediate in cholesterol biosynthesis and 2,3:22,23-dioxidosqualene act as the substrate for an alternative pathway that produces 24(S),25-epoxycholesterol which effects cholesterol homeostasis. In light of our previous findings con... |
|
|
FDA-approved drug labeling for the study of drug-induced liver injury.
Drug Discov. Today 16 , 697-703, (2011) Drug-induced liver injury (DILI) is a leading cause of drugs failing during clinical trials and being withdrawn from the market. Comparative analysis of drugs based on their DILI potential is an effective approach to discover key DILI mechanisms and risk fact... |
|
|
In vivo phosphoantigen levels in bisphosphonate-treated human breast tumors trigger Vγ9Vδ2 T-cell antitumor cytotoxicity through ICAM-1 engagement.
Clin. Cancer Res. 18(22) , 6249-59, (2012) Nitrogen-containing bisphosphonates (N-BP) such as zoledronate and risedronate exhibit antitumor effects. They block the activity of farnesyl pyrophosphate synthase (FPPS) in the mevalonate pathway, leading to intracellular accumulation of mevalonate metaboli... |
|
|
Biosorption of heavy metal ions onto agricultural residues buckwheat hulls functionalized with 1-hydroxylethylidenediphosphonic acid.
J. Agric. Food Chem. 60(47) , 11664-74, (2012) Novel biosorbent materials obtained from agricultural residues buckwheat hulls (BH) were successfully developed through functionalization with 1-hydroxylethylidenediphosphonic acid (HEDP), and they were characterized. This paper reports the feasibility of usi... |
|
|
Atorvastatin, etidronate, or both in patients at high risk for atherosclerotic aortic plaques: a randomized, controlled trial.
Circulation 127(23) , 2327-35, (2013) Statins are not effective in reducing atherosclerotic plaques of the abdominal aorta, and accumulating evidence suggests that bisphosphonates have the potential to induce the regression of atherosclerotic plaques of the abdominal aorta.A prospective, randomiz... |
|
|
Etidronic acid. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.
Drugs Aging 5(6) , 446-74, (1994) Etidronic acid is an orally and intravenously active bisphosphonate, which is believed to inhibit resorption of bone via a number of cellular mechanisms, including alteration of osteoclastic activity. In studies of patients with symptomatic Paget's disease, e... |
|
|
A meta-analysis characterizing the dose-response relationships for three oral nitrogen-containing bisphosphonates in postmenopausal women.
Osteoporos. Int. 24(1) , 253-62, (2013) A meta-analysis of spine BMD dose-response relationships for alendronate, risedronate, and ibandronate was performed. Data from all three oral bisphosphonates conform to a log-linear relationship between dose and change in spine BMD relative to placebo at 1 y... |
|
|
Oral bisphosphonates: early endosseous dental implant success and crestal bone changes. A retrospective study.
Int. J. Oral Maxillofac. Implants 27(5) , 1216-22, (2012) The purpose of this retrospective chart-review study was to compare the early success rate and the crestal bone changes of dental implants in patients taking oral bisphosphonates at the time of implant placement to those of patients who had never taken bispho... |
|
|
Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years.
Osteoporos. Int. 24(1) , 301-10, (2013) Bone mineral density response to once weekly delayed-release formulation of risedronate, given before or following breakfast, was non-inferior to that seen with traditional immediate-release risedronate given daily before breakfast. Delayed-release risedronat... |